Table 6
From: Cost-utility analysis of a national project to reduce hypertension in Israel
Appendix II: Key Epidemiologic Variables | Â | Reference/Data Source |
|---|---|---|
EPIDEMIOLOGIC | Â | Â |
Male life expectancy at age 60 (years) | 20.9 | 12 |
Female life expectancy at age 60 (years) | 23.4 | 12 |
Healthy Adjusted Life expectancy at age 60 males | 16.8 | 24 |
Healthy Adjusted Life expectancy at age 60 females | 18.2 | 24 |
Hypertension | Â | Â |
% hypertensive cases, Males 25–44 | 3.8% | 12 |
% hypertensive cases, Males 45–54 | 14.7% | 12 |
% hypertensive cases, Males 55–64 | 27.8% | 12 |
% hypertensive cases, Females 25–44 | 3.2% | 12 |
% hypertensive cases, Females 45–54 | 13.9% | 12 |
% hypertensive cases, Females 55–64 | 34.5% | 12 |
% of persons treated successfully in program | 50% | 9,10,13 |
Acute MI | Â | Â |
Annual Incidence | 8940 | 14 |
% AMI in Males | 77.0% | 14 |
20 year MI risk at age 25 | 5.0% | 11 |
20 year MI risk at age 30 | 7.5% | 11 |
20 year MI risk at age 35 | 10.0% | 11 |
20 year MI risk at age 40 | 16.0% | 11 |
20 year MI risk at age 45 | 22.0% | 11 |
20 year MI risk at age 50 | 27.0% | 11 |
20 year MI risk at age 55 | 32.0% | 11 |
20 year MI risk at age 60 | 41.0% | 11 |
20 year MI risk at age 65 | 50.0% | 11 |
Annual increase in MI risk over 20 years | 1.0% | Assumed |
Decrease in risk of MI in persons successfully treated | 16.0% | 9,10,15–17 |
Health Status Valuation of MI patient | 0.61 | 25 |
Years in decreased health state. | 0.06 | 26 |
Unstable Angina Pectoris | Â | Â |
Annual Incidence | 3354 | 14 |
% UAP in males | 73.9% | 14 |
Decrease in risk of UAP in persons succesfully treated | 16.0% | 9,10,15–17 |
Health Status Valuation of UAP patient | 0.91 | 25 |
Years in decreased health state. | 1.00 | 26 |
Stroke | Â | Â |
Mean age of stroke | 73.2 | 19 |
% strokes in males | 58.2% | 19 |
Relative Risk of Stroke in Hypertensive cases | 1.7 | 19 |
Stroke rate per 1000 aged 45–55 | 1.14 | 19 |
Stroke rate per 1000 aged 55–64 | 2.28 | 19 |
Stroke rate per 1000 aged 65–74 | 5.11 | 19 |
Stroke rate per 1000 aged 75–84 | 9.86 | 19 |
Decrease in Stroke risk in persons successfully treated | 41.2% | 19 |
Health Status Valuation of first ever stroke patient | 0.78 | 25 |
Years in decreased health state. | 7.80 | 26 |
Chronic Renal Failure | Â | Â |
ESRD incidence rates per 100,000 Males 45–54 | 31.9 | 19 |
ESRD incidence rates per 100,000 Males 55–64 | 77.8 | 19 |
ESRD incidence rates per 100,000 Males 65–74 | 148.7 | 19 |
ESRD incidence rates per 100,000 Males 75+ | 174.2 | 19 |
ESRD incidence rates per 100,000 Females 45–54 | 16.7 | 19 |
ESRD incidence rates per 100,000 Females 55–64 | 44.6 | 19 |
ESRD incidence rates per 100,000 Females 65–74 | 88.5 | 19 |
ESRD incidence rates per 100,000 Females 75+ | 71.9 | 19 |
Decrease in ESRD risk in persons successfully treated | 49.9% | 10 |
Health Status Valuation of ESRD | 0.904 | 28 |
PVD | Â | Â |
PVD incidence per 1000 male hypertensive cases | 6.20 | 23 |
PVD incidence per 1000 female hypertensive cases | 3.65 | 23 |
PVD Relative Risk in Hypertensive to Normotensive cases | 2.31 | 23 |
PVD Relative Risk in Hypertensive to controlled cases | 1.40 | 23 |
Attainable risk reduction Hypertensive to Normotensive cases | 56.8% | 23 |
Attainable risk reduction Hypertensive to Controlled cases | 28.4% | 23 |
% treated who become controlled cases | 50% | 9,10 |
% treated who become normotensive cases | 50% | 9,10 |